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a  b  s  t  r  a  c  t
Cellular  metabolic  state  and  individual  metabolites  have  been  reported  to  regulate  the  functional  phe-
notype  of  immune  cells.  Cytokine  production  by  regulatory  and  inﬂammatory  macrophages  is  thought
to mainly  involve  fatty  acid oxidation  and  glycolysis,  respectively,  which  fuel  mitochondrial  oxidative
phosphorylation.  However,  the association  between  metabolic  pathways  and  the acquisition  of speciﬁc
macrophage  phenotypes  remains  unclear.  This  study  assessed  the  relationship  between  glycolysis  and  the
differentiation  of regulatory  macrophages.  Human  monocytes  derived  from  peripheral  blood  were  cul-
tured in  vitro  in the  presence  of  macrophage  colony-stimulating  factor  to yield  regulatory  macrophages
(M-Ms).  M-Ms  had  a regulatory  macrophage  phenotype  and  produced  substantial  IL-10  following
stimulation  with  lipopolysaccharide.  To  analyze  the role  of  glycolysis,  glycolysis  inhibitors  (2-deoxy-d-
glucose  or  dichloroacetate)  were  added  during  M-M  differentiation.  These  cells  cultured  with  glycolysis
inhibitors  produced  signiﬁcantly  lower  amounts  of  IL-10,  but  produced  signiﬁcantly  higher amounts  of
IL-6  compared  to M-Ms  differentiated  without  glycolysis  inhibitors.  Such  phenotypic  change  of  M-
Ms  differentiated  with  glycolysis  inhibitors  was  associated  with  the  alteration  of the  gene  expression
pattern  related  to  macrophage  differentiation,  such  as  CSF1,  MMP9  and  VEGFA.  M-Ms  differentiated
with  glycolysis  inhibitors  seemed  to  retain  plasticity  to  become  IL-10  producing  cells.  Furthermore,
increased  level  of  pyruvate  in culture  medium  was  found  to partially  reverse  the  effects  of  glycolysis
inhibitors  on  cytokine  production  of M-Ms.  These  results  indicate  the  importance  of  glycolytic  pathway
in  macrophage  differentiation  to a  regulatory  phenotype,  and  pyruvate  may  be  one  of  the  key metabolites
in this  process.
© 2016  The  Authors.  Published  by Elsevier  B.V.  on  behalf  of European  Federation  of  Immunological
Societies.  This  is  an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/Abbreviations: M-CSF, macrophage colony-stimulating factor; IFN-, interferon-
amma; M-M, macrophage differentiated from CD14 positive monocytes in
he presence of M-CSF; M-M,  macrophage differentiated from CD14 positive
onocytes in the presence of M-CSF and IFN-; 2-DG, 2-deoxy-d-glucose; DCA,
ichloroacetate; TCA, tricarboxylic-acid; LPS, lipopolysaccharide; C type 1;IDO1,
ndoleamine 2,3-dioxygenase 1; CSF1, colony stimulating factor 1; MMP9, matrix
etallopeptidase 9; VEGFA, vascular endothelial growth factor A; PDK, pyruvate
ehydrogenase kinase.
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1. Introduction
Macrophages, which are widely distributed in a variety of organs
[1], play important roles in regulating inﬂammatory responses
in a context dependent manner [2]. Phenotypes of macrophages
are determined by environmental stimuli. Mirroring the Th1-
Th2 polarization of T cells, polarized macrophages are often
referred to as inﬂammatory (M1  or classically activated) and
regulatory (M2  or alternatively activated) macrophage [3]. Inﬂam-
matory macrophages are involved in anti-microbial responses
and express high levels of pro-inﬂammatory cytokines, includ-
ing tumor necrosis factor  (TNF-),  interleukin (IL)-6, IL-12, and
IL-23. In contrast, regulatory macrophages are thought to have
critical roles in the termination of inﬂammation by producing the
n of Immunological Societies. This is an open access article under the CC BY-NC-ND
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Table  1
Quantitative PCR primers used in this study.
Gene Symbol Forward (5′-3′) Reverse (5′-3′)
CCL22 GGTATTTGAACCTGTGGAATTGGAG CAGGCCCTGGATGACACTGA
IDO1 AGACTGTGTCTTGGCAAACTGGAA TGCATTGCCTTGAATACAGTAGGAA
CSF1 TCGGAGTACTGTAGCCACATGATTG TGGCACGAGGTCTCCATCTG
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VEGFA CTGGAGTGTGTGCCCACTGA 
18S rRNA ACTCAACACGGGAAACCTCA 
nti-inﬂammatory cytokine IL-10 [4–8]. It has also been reported
hat regulatory macrophages promote tissue repair, contribute to
etabolic homeostasis and are involved in immunity against par-
sitic helminth infections [1,9–11].
Metabolic pathways, including oxidative phosphorylation, gly-
olysis and lipolysis, are actively involved in determining cell
ate and in the effector functions of immune cells [12,13]. Acti-
ation of mature inﬂammatory and regulatory macrophages is
haracterized by distinct metabolic states. Activation of inﬂam-
atory macrophages is dependent on aerobic glycolysis, a process
mportant for the production of reactive oxygen species for host
efenses against microbes [14]. In addition, some of the metabo-
ites resulting from glycolysis and the tricarboxylic-acid (TCA) cycle
re important in regulating the immunological reactions of inﬂam-
atory macrophages [15–17]. In contrast, activation of regulatory
acrophages involves the use of fatty acid oxidation to fuel mito-
hondrial oxidative phosphorylation [18,19].
Although glycolysis has an established role in the activation of
nﬂammatory macrophages, little is known about the association
etween glycolysis and acquisition of the regulatory macrophage
henotype. Unraveling the relationships between metabolism and
he differentiation of regulatory macrophages would have impor-
ant implications for the homeostatic roles of these cells [1,2].
This study therefore analyzed the roles of glycolysis in
he in vitro differentiation of human monocytes to regulatory
acrophages. Our results suggest that glycolysis is essential for
acrophages to differentiate into an IL-10 producing phenotype,
nd that pyruvate is a key metabolite during the process of regula-
ory macrophage differentiation.
. Materials and methods
.1. In vitro monocyte differentiation
This study was conducted in accordance with the Declara-
ion of Helsinki, and the protocol was approved by the ethics
ommittees of Keio University School of Medicine (Approval Num-
er; 20090259). Signed informed consent forms were obtained
rom all donors and all data were analyzed anonymously through-
ut the study. Ten healthy donors participated in this study.
eripheral blood mononuclear cells collected from healthy donors
ere isolated from 30 mL  of heparinized peripheral blood samples
y density gradient centrifugation using LymphoPrep (Nycomed
harma, Oslo, Norway). Cells were aspirated from the gradi-
nt interface, washed with PBS, and resuspended in RPMI-1640
edium (Sigma-Aldrich, St Louis, MO)  containing 10% heat-
nactivated fetal bovine serum (Life Technologies, Carlsbad, CA),
00 U/ml penicillin and 100 mg/ml  streptomycin (Life Technolo-
ies). Monocytes were puriﬁed using a magnetic cell separation
ystem (MACS; Miltenyi Biotec, Auburn, AL) with anti-human
D14 microbeads (Miltenyi Biotec), and were seeded in 6-well
lates at 1 × 106 cells/well. The culture medium contained 50 ng/ml
acrophage colony-stimulating factor (M-CSF; R&D Systems,
inneapolis, MN)  to induce the production of M-CSF differen-
iated macrophages (M-Ms), or 50 ng/ml M-CSF and 100 ng/ml
nterferon-gamma (IFN-; R&D) to induce the production of M-CATCTCTGCCACCCGAGTGTA
CATTCACATTTGTTGTGCTGTAGGA
AACCAGACAAATCGCTCCAC
CSF and IFN- differentiated macrophages (M-Ms). Glycolysis
was inhibited during differentiation by adding 2-deoxy-d-glucose
(2-DG; Sigma-Aldrich) or dichloroacetate (DCA; Sigma-Aldrich) at
indicated concentrations. After 6 days, the cells were trypsinized
and harvested with a cell scraper; these cells were deﬁned as com-
pletely differentiated macrophages.
2.2. Stimulation of in vitro differentiated macrophages
The differentiated macrophages described above were seeded
in 96-well culture dishes at 1 × 105 cells/well and stimulated for
20 h with 100 ng/ml of lipopolysaccharide from Escherichia coli
0111:B4 (LPS; Sigma Aldrich), and the supernatants were collected
for cytokine assays. TNF-, IL-10, and IL-6 concentrations were
measured using a Human Inﬂammatory Cytokine Kit (Cytometric
Beads Assay series; BD Biosciences, San Diego, CA), according to the
manufacturer’s instructions. The cells were subsequently analyzed
using a FACSCalibur system (BD Biosciences).
2.3. Quantitative RT-PCR
Total RNA was isolated from macrophages using NucleoSpin
RNA kits (Takara Bio Inc., Shiga, Japan). For quantitative RT-PCR,
a One-Step PrimeScript RT-PCR Kit (Takara Bio Inc.) was used
with speciﬁc primers for CCL22,  indoleamine 2,3-dioxygenase 1
(IDO1), colony stimulating factor 1 (CSF1), matrix metallopeptidase 9
(MMP9), vascular endothelial growth factor A (VEGFA) and 18S rRNA
(Table 1). PCR ampliﬁcations were performed using a CFX96 Real-
Time System (Bio-Rad Laboratories, Inc., Hercules, CA), and relative
expression was  determined by normalization to the ampliﬁcation
of the 18S rRNA sequence.
2.4. Flow cytometric analysis
Cells were incubated with monoclonal antibodies against CD14,
CD33, CD163, CD206, CD209, and HLA-DR and with isotype con-
trols (BioLegend; San Diego, CA). The ﬂuorescence intensity of
the labeled cell surface markers was  assessed using a FACSCalibur
ﬂow cytometer (BD Biosciences), and the data were analyzed using
FLOWJO (FlowJo, Ashland, OR) software. Dead cells were excluded
from analyses by 7-AAD (BD Biosciences) staining.
2.5. Respiratory activity assay
Cellular respiratory activity was measured using XF Mito Stress
Test Kits (Seahorse Bioscience, North Billerica, MA)  according to the
manufacturer’s instructions. Oxygen consumption rate (OCR, equal
to mitochondrial respiration) was  measured using an XF24 ana-
lyzer (Seahorse bioscience). Brieﬂy, cells were seeded at 1.6 × 105
cells/well the day before the experiment. Basal and maximal
respiratory activities were determined. Cellular maximal respi-
ratory activity was  determined by adding 0.75 M oligomycin,
an inhibitor of complex V (ATP synthase), followed by 0.75 M
carbonyl cyanide-p-triﬂuoromethoxyphenylhydrazone (FCCP), an
uncoupler of mitochondrial oxidative phosphorylation.
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Table 2
The 10 genes most up-regulated in 2DG-treated M-M compared with M-M.
Rank Gene Symbol Gene Name log2 ratio, M+/M−
1 SLC6A9 solute carrier family 6 (neurotransmitter transporter, glycine), member 9 8.13
2  ASS1 argininosuccinate synthase 1 7.46
3  EEF1A2 eukaryotic translation elongation factor 1 alpha 2 7.12
4  KCNG1 potassium voltage-gated channel, subfamily G, member 1 7.09
5  WNT5A wingless-type MMTV  integration site family, member 5A 6.73
6  IL6 interleukin 6 (interferon, beta 2) 6.52
7  PSAT1 phosphoserine aminotransferase 1 6.40
8  CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 6.25
9  OR1N1 olfactory receptor, family 1, subfamily N, member 1 5.64
10  ASNS asparagine synthetase (glutamine-hydrolyzing) 5.60
Gene expression levels from micro array analysis (Fig. 3) are presented as a ratio of normalized intensity (log2).
Fig. 1. M-Ms have a regulatory macrophage phenotype and IL-10 producing activity compared with M-Ms.  (A) Morphological phenotypes of M-Ms and M-Ms
differentiated in vitro from peripheral CD14 positive monocytes. (B) Expression levels of IDO1 and CCL22 mRNAs, as determined by real-time quantitative PCR and normalized
relative to the amount in each sample of 18S rRNA. Data indicate the fold expression compared with M-Ms (n = 3). (C) Levels of cytokines produced by stimulation of M-Ms
a s and
c esent 
t
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Rnd  M-Ms  with 100 ng/ml LPS for 20 h (n = 4). (D) Respiratory activity of M-M
onsumption rate (OCR) was determined using an XF24 analyzer (n = 5). Data repr
-tests (B, C, D)..6. Microarray analysis
Total RNA samples were extracted from macrophages using an
Neasy Mini Kit (Qiagen, Hilden, Germany). Equal amounts of RNA M-Ms, as measured using Mito Stress tests (Seahorse Bioscience). The oxygen
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 compared with M-Ms by Student’sfrom 3 individuals were mixed. The following assays and analy-
ses were performed at Chemical Evaluation and Research Institute
(CERI, Tokyo, Japan). RNA was subjected to quality control analysis
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Fig. 2. Inhibition of glycolysis during M-M differentiation results in the loss of IL-10 producing phenotype and other regulatory macrophage characteristics. (A) Schematic
diagram of the experiments. (B) Morphological phenotypes of M-Ms differentiated in the presence or absence of 2-DG or DCA. (C) Macrophages were stained with indicated
mAbs  and analyzed by ﬂow cytometry. The shaded histogram shows the proﬁles of the indicated antibody staining and the open histogram shows staining of isotype
controls. Representative data from three individual experiments are shown. (D) Levels of expression of IDO1 and CCL22 mRNAs were analyzed by real-time quantitative PCR
and  normalized relative to the amount of 18S rRNA in the same samples. The numbers indicate fold expression compared with M-Ms (n = 3). *p < 0.05, **p < 0.01 compared
with  M-Ms by Dunnett’s type multiple comparison test. #p < 0.05 compared with M-Ms  by Dunnett’s type multiple comparison test. (E) Levels of cytokines produced
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(y  M-Ms differentiated in the presence or absence of glycolysis inhibitors (3 mM 2
ean  ± SEM. *p < 0.05, ***p < 0.001 compared with M-Ms differentiated in the abs
nd reverse transcribed and labeled by using Quick-Amp Label-
ng Kits (Agilent Technologies, Santa Clara, CA). The labeled cDNA
as hybridized to SuperPrint G3 Human GE microarray (8 × 60 K)
er.2 (Agilent Technologies). The microarray was scanned with a
NA Microarray Scanner (Agilent Technologies) and the expres-
ion proﬁles were analyzed with Feature Extraction ver. 10.7.1.1
Agilent Technologies). Signal intensities were normalized to ther 20 mM DCA) and stimulated with 100 ng/ml LPS for 20 h (n = 5–7). Data represent
f inhibitor by Student’s t-tests.
mean intensity of all the genes represented on the array. Microar-
ray data are available from the National Center for Biotechnology
Information’s Gene Expression Omnibus under accession number
GSE74182. Canonical pathway analysis was generated using QIA-
GEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City,
www.qiagen.com/ingenuity).
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Table 3
The 10 genes most down-regulated in 2DG-treated M-M compared with M-M.
Rank Gene Symbol Gene Name log2 ratio, M+/M−
1 GAL galanin/GMAP prepropeptide 2.15 × 10−3
2 SPC25 SPC25, NDC80 kinetochore complex component 6.77 × 10−3
3 BIRC5 baculoviral IAP repeat containing 5 6.96 × 10−3
4 KIAA0101 KIAA0101 7.59 × 10−3
5 FA2H fatty acid 2-hydroxylase 7.75 × 10−3
6 CHIT1 chitinase 1 (chitotriosidase) 8.86 × 10−3
7 CRABP2 cellular retinoic acid binding protein 2 8.99 × 10−3
8 MRGPRF MAS-related GPR, member F 9.43 × 10−3
9 HIST2H3A histone cluster 2, H3a 1.07 × 10−2
10 DUSP13 dual speciﬁc
Gene expression levels from micro array analysis (Fig. 3) are presented as a ratio of norm
Table 4
Top 5 canonical pathways of genes up-regulated in 2DG-treated M-M compared
with M-M.
Rank Name p-value Ratio
1 Hematopoiesis from Pluripotent Stem Cells 2.08 × 10−7 12/33 (36%)
2  Primary Immunodeﬁciency Signaling 2.22 × 10−6 12/40 (30%)
3  Endoplasmic Reticulum Stress Pathway 1.45 × 10−4 7/21 (33%)
4  T Cell Receptor Signaling 1.31 × 10−3 14/94 (15%)
5  tRNA Charging 1.53 × 10−3 8/38 (21%)
The canonical pathway analyses were based on micro-array data (Fig. 3). Log2 ratios
of gene expression were analyzed using Ingenuity Pathway Analysis (IPA® version
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h8841524, QIAGEN Redwood City,). P-value expresses the signiﬁcance of the rela-
ionship for the pathway. The numbers of genes whose expression level are changed
n  each pathway are expressed as “Ratio”.
.7. Cellular metabolite analysis
Cellular metabolites were extracted with a methanol contain-
ng internal standard solution (Human Metabolome Technologies,
amagata, Japan). Cationic metabolites were measured by capillary
lectrophoresis–connected time-of-ﬂight mass spectrometry (CE-
OFMS, Agilent Technologies) and anionic compounds by positive
nd negative modes of CE-MS/MS (Agilent Technologies).
.8. Statistical analysis
All data are expressed as mean ± SEM. Data were compared
sing Student’s t-test or Dunnett’s type multiple comparison test,
ith p < 0.05 deﬁned as statistically signiﬁcant.
. Results
.1. M-Ms have regulatory macrophage phenotypes
Phenotypes of the regulatory macrophages (M-Ms) used in
his study were compared to the inﬂammatory macrophages (M-
s). M-Ms and M-Ms  were differentiated in vitro from
onocytes in the presence of M-CSF and of M-CSF plus IFN-,
espectively. M-Ms exhibited a spindle-like adhesive morphol-
gy, distinct from the spherical and non-adhesive M-Ms  (Fig. 1A)
20]. Compared with M-Ms,  M-Ms expressed signiﬁcantly
igher levels of the regulatory macrophage-related gene, CCL22,
nd a lower level of the inﬂammatory macrophage-related gene,
DO1 (Fig. 1B) [21]. M-Ms stimulated with LPS produced larger
mounts of the anti-inﬂammatory cytokine, IL-10, and smaller
mounts of the pro-inﬂammatory cytokines, IL-6 and TNF-,
han LPS-stimulated M-Ms  (Fig. 1C). We  also analyzed the
etabolic states of macrophages using a Flux analyzer. Regulatory
acrophages have been reported to mainly use mitochondrial res-
iration, whereas inﬂammatory macrophages have been found to
ely on glycolysis [17,19]. The maximal potential of respiration was
igher in M-Ms than in M-Ms,  suggesting that the former hasity phosphatase 13 1.07 × 10−2
alized intensity (log2).
a metabolic state closer to regulatory macrophages (Fig. 1D). Taken
together, we  used M-Ms for the analysis of the differentiation of
regulatory macrophages.
3.2. Glycolysis inhibition during M-M differentiation alters its
characters
To investigate the role of glycolysis during the differentiation of
monocytes into regulatory macrophages, M-Ms were incubated
with 2-DG or DCA to inhibit glycolysis [22,23]. 2-DG is phosphory-
lated by hexokinase, but cannot be further metabolized, resulting
in the inhibition of hexokinase. In contrast, DCA inhibits pyruvate
dehydrogenase kinase (PDK) by mimicking pyruvate, shifting cel-
lular metabolism from glycolysis to oxidative phosphorylation. As
the schematic diagram shown in Fig. 2A, M-Ms were differenti-
ated in the presence of 2-DG or DCA and their phenotypes were
determined. Cells differentiated in the presence of 2-DG lost their
adhesive phenotype and showed a distinct pattern of cell surface
antigens, expressing Siglec-3 (CD33), scavenger receptor (CD163),
mannose receptor (CD206), and DC-SIGN (CD209) more strongly,
and HLA-DR more weakly, than M-Ms (Fig. 2B, C) as previously
reported [20,24]. The patterns of cell surface antigens of DCA-
treated M-Ms were similar to that of M-Ms. M-Ms  showed
different patterns of cell surface antigens from that of M-Ms dif-
ferentiated with or without 2-DG and DCA. M-Ms differentiated in
the presence of 2-DG or DCA showed similar expression of CCL22
to M-Ms  (Fig. 2D). Whereas, similar to M-Ms differentiated
without 2-DG or DCA, M-Ms differentiated with 2-DG or DCA
showed reduced expression of IDO1 compared to M-Ms.  Fur-
thermore, these M-Ms differentiated in the presence of glycolysis
inhibitors produced signiﬁcantly lower amounts of IL-10, but pro-
duced signiﬁcantly higher amounts of IL-6 and similar amounts
of TNF-, compared with M-Ms differentiated in the absence of
glycolysis inhibitors (Fig. 2E). It is shown that inhibition of glycol-
ysis during the differentiation of M-Ms results in the loss of their
characteristic cytokine production patterns independent of other
phenotypes.
3.3. Expression of genes essential for macrophage differentiation
are affected by glycolysis inhibitors
The gene expression patterns of macrophages were analyzed
to understand the mechanism underlying the ability of glycoly-
sis inhibitors to regulate macrophage phenotypes. A microarray
analysis identiﬁed 2345 probes up-regulated more than 2-fold,
and 2284 probes down-regulated less than 0.5-fold, in M-Ms dif-
ferentiated in the presence than in M-Ms differentiated in the
absence of 2-DG (Fig. 3A). The expression of several genes related
to metabolic pathways, such as SLC6A9, ASS1, PSAT1,  ASNS and
FA2H, differed dramatically in these two cell types (Tables 2 and 3).
Hierarchical clustering showed that the gene expression pattern
H. Suzuki et al. / Immunology Letters 176 (2016) 18–27 23
Fig. 3. M-Ms differentiated in the presence of 2-DG and DCA have distinct gene expression patterns (A) Scatter plot for gene expression by M-Ms (M,  −) versus M-Ms
differentiated in the presence of 2-DG (M,  +). Gene expression data from DNA microarray analyses were normalized globally using GeneSpring GX 12.0 (Agilent). Purple
and  green lines represent >2-fold and <0.5-fold gene expression by 2-DG-treated M-Ms compared with M-Ms, respectively. (B) Ward’s hierarchical clustering of gene
expression patterns by monocytes (Mo), M-Ms (M,  −), 2-DG-treated M-Ms (M,  +), M-Ms (M,  −), and M-Ms  differentiated in the presence of 2-DG (M,  +). The ﬁve
samples used in this analysis detected 23,776 probes. (C) Gene expression levels in 2-DG-treated M-Ms relative to M-Ms presented as a ratio of normalized intensity
(log2)  by heat map. Genes related to macrophage differentiation (GO: 0030225) were selected for analysis. (D) Quantitative real-time RT-PCR of the levels of expression of
CSF-1,  MMP9, and VEGFA mRNAs. The level of expression in each sample was normalized relative to the amount of 18S rRNA in that sample. Data indicate fold expression
compared with M-Ms (n = 3). *p < 0.05 compared with M-Ms by Dunnett’s type multiple comparison test.
Table 5
Top 5 canonical pathways of genes down-regulated in 2DG-treated M-M compared with M-M.
Rank Name p-value Ratio
1 Dendritic Cell Maturation 6.57 × 10−9 36/158 (23%)
2  OX40 Signaling Pathway 1.11 × 10−8 18/48 (38%)
3  Allograft Rejection Signaling 1.60 × 10−8 16/39 (41%)
4  LXR/RXR Activation 1.50 × 10−7 28/119 (24%)
5  Hepatic Fibrosis/Hepatic Stellate Cell Activation 1.85 × 10−7 38/194 (20%)
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the canonical pathway analyses were based on micro-array data (Fig. 3). Log2 ra
8841524, QIAGEN Redwood City,). P-value expresses the signiﬁcance of the relatio
athway are expressed as “Ratio”.f 2-DG-treated M-Ms was closer to M-Ms than monocytes
nd M-Ms  (Fig. 3B). Canonical pathway analysis on IPA iden-
iﬁed 1524 of the 2345 up-regulated probes and 1657 of the 2282 gene expression were analyzed using Ingenuity Pathway Analysis (IPA® version
for the pathway. The numbers of genes whose expression level are changed in eachdown-regulated probes in 2-DG-treated M-Ms than in M-Ms.
Top 5 pathways signiﬁcantly up-regulated or down-regulated in
ascending order are listed in Tables 4 and 5. Canonical pathway
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Fig. 4. M-Ms differentiated in the presence of 2-DG retain plasticity. (A) Schematic
diagram of the experiments. (B) Morphological phenotypes of macrophages cultured
in  the indicated conditions on days 6 and 11. (C) Macrophages cultured in the indi-4 H. Suzuki et al. / Immuno
nalysis revealed that 2-DG altered the pathways involved in the
egulation of cellular differentiation (hematopoiesis from pluripo-
ent stem cells and dendritic cell maturation) and inﬂammatory
athways (primary immunodeﬁciency signaling, T cell receptor sig-
aling, dendritic cell maturation, OX40 (CD134) signaling, allograft
ejection signaling, and hepatic ﬁbrosis/hepatic stellate cell activa-
ion).
Expression levels of genes related to macrophage differentia-
ion (GO: 0030225) in the microarray were shown in Fig. 3C. The
iggest changes were found in the levels of expression of CSF1,
MP9  (decrease) and VEGFA (increase) when expression levels of
enes in cultured cells in the presence of 2-DG were compared to
ifferentiated cells in the absence of 2-DG (Fig. 3C). Quantitative
CR analysis showed that the levels of expression of CSF1 and MMP9
ere signiﬁcantly lower in M-Ms differentiated in the presence
han in the absence of 2-DG, with similar results observed when M-
s were differentiated in the presence of DCA (Fig. 3D). The level
f expression of VEGFA was up-regulated by glycolysis inhibitors
hough the increase by 2-DG was not statistically signiﬁcant.
.4. M-Ms differentiated with 2-DG retain plasticity
To test whether glycolysis inhibition affects cell fate perma-
ently, the plasticity of 2-DG-treated M-Ms was assessed (Fig. 4A).
-Ms were differentiated in the presence of 2-DG for 6 days,
hen the differentiation medium was changed to the same medium
ithout 2-DG, and culture was continued. On day 11 (5 days after
he removal of 2-DG containing culture medium), cells had a
pindle-like adhesive phenotype (Fig. 4B) and produced compara-
le amounts of IL-10 and IL-6 to those produced by 2-DG-untreated
-Ms, whereas M-Ms differentiated in the presence of 2-DG for
 days produced signiﬁcantly smaller amounts of IL-10 and larger
mounts of IL-6 compared to 2-DG-untreated M-Ms (Figs. 4C).
hese results indicate that M-Ms differentiated for 6 days in the
resence of 2-DG are sufﬁciently plastic to revert to an M-M-like
henotype by 5 days of 2-DG free condition of differentiation.
.5. Pyruvate is a key metabolite for M-M function
We  hypothesized that key metabolites which strongly regu-
ate macrophage differentiation may  exist in glycolytic pathway.
o investigate this hypothesis, we used M-Ms differentiated in
he presence of DCA rather than 2-DG, because DCA does not com-
letely shut down the entire ﬂux of glycolytic pathway [23]. We
ound that the presence of DCA affected the concentration of sev-
ral metabolites related to the glycolytic pathway and TCA cycle
efore and after LPS stimulation (Fig. 5A). Notably, M-Ms differ-
ntiated in the presence of DCA showed a marked difference from
ells differentiated in the absence of DCA in pyruvate concentra-
ion after LPS stimulation (Fig. 5A). Because DCA promotes pyruvate
onsumption by accelerating its utilization in the TCA cycle [25,26],
e focused on pyruvate as a key molecule. To analyze the effect
f pyruvate, pyruvate was added to the culture medium during
he differentiation of M-Ms, with or without DCA (Fig. 5B). The
ddition of pyruvate alone had no effect on the index of functional
ifferentiation of M-Ms, such as the production of IL-6 and IL-
0. In contrast, the addition of pyruvate to M-Ms differentiated
n the presence of DCA resulted in a signiﬁcant reduction in IL-6
roduction, but had no effect on IL-10 production (Fig. 5C). These
esults may  indicate that the phenotypic changes observed in M-
s differentiated in the presence of DCA were due to the effect of
yruvate at least in the property to produce IL-6.cated condition were stimulated with 100 ng/ml LPS for 20 h (n = 3–4) and the levels
of  IL-10, IL-6 and TNF expression were measured. Data represent mean ± SEM.
**p  < 0.01 compared with control by Student’s t-tests.
4. Discussion
This study investigated the roles of glycolytic pathway in the dif-
ferentiation of macrophages to a regulatory phenotype, and offered
a new insight into the regulation of macrophage differentiation by
glycolytic pathway. We found that inhibition of glycolysis during
the differentiation of M-Ms resulted in the loss of its regulatory
macrophage phenotypes including cytokine production patterns.
Remarkably, these effects on cytokine production by glycolysis
inhibitors were partially reverted by the addition of pyruvate to
the culture medium. Therefore, these results indicate that gly-
colytic pathway is involved in the differentiation of regulatory
macrophages by providing the key metabolite for their differen-
tiation.
Using microarray and quantitative PCR analyses, we revealed
the involvement of glycolytic pathway in the regulation of gene
H. Suzuki et al. / Immunology Letters 176 (2016) 18–27 25
Fig. 5. Cellular metabolites are involved in the regulation of M-Ms (A) M-Ms differentiated in the presence or absence of 20 mM DCA were seeded onto a new plate and
stimulated with 100 ng/ml LPS for 0–3 h. Representative metabolites in the glycolytic pathway and TCA cycle are shown. Data are expressed relative concentration to M-Ms
differentiated in the absence of DCA and without LPS stimulation (n = 1). (B) Schematic diagram of the experiments. (C) Levels of cytokine production by M-Ms differentiated
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xpression related to macrophage differentiation. CSF1, which
ncodes M-CSF, and MMP9  were found to be down-regulated
n M-Ms differentiated in the presence of glycolysis inhibitors.
lthough circulating M-CSF is thought to be secreted by endothe-
ial cells of many organs [27], it is also locally synthesized by
acrophages, mainly its membrane-spanning cell surface form
28], and locally synthesized M-CSF contributes to the differentia-
ion of macrophages [4,29–33]. MMP-9 is preferentially expressed
n macrophages and regulates key macrophage functions, such as
he angiogenic capacity of M2  macrophages and cellular migra-
ion [34,35]. Down-regulation of M-CSF and MMP-9 by inhibiting
lycolysis should have altered the differentiation of M-Ms. On
he contrary, up-regulation of VEGFA in M-Ms differentiated
n the presence of glycolysis inhibitors might have induced the
nﬂammatory phenotype of M-Ms (increased IL-6 production or
omparable gene expression of CCL22 to M-Ms),  since VEGFA is
ownstream of NF-B [36]. On the other hand, microarray analysis
evealed that the gene expression pattern of M-Ms differentiated
n the presence of 2-DG was closer to that of M-Ms than of mono-
ytes, and M-Ms  differentiated in the presence or absence of
-DG. Thus, global gene expression pattern suggested that inhi-
ition of glycolysis did not promote differentiation toward anml LPS for 20 h (n = 4). Data represent mean ± SEM. *p < 0.05, ** p < 0.01, ***p < 0.001
pe multiple comparison test. #p < 0.05 compared with M-Ms differentiated in the
.
inﬂammatory, M-M-like phenotype. However, detailed investi-
gation of the alteration in global gene expression pattern including
the results of canonical pathway analysis should be conducted in
the future work.
Macrophages are thought to be highly plastic. Depending on
the environmental cues, macrophages can change their phenotype
from an inﬂammatory to a regulatory phenotype and vice versa
[37–39]. Porcheray et al., demonstrated inﬂammatory and regula-
tory macrophages were rapidly and fully reversible by treating with
a counterstimulatory cytokine [38]. Moreover Das  et al., showed
that efferocytosis switched macrophages to an anti-inﬂammatory
phenotype through the action of microRNA21 [39]. Plasticity of
macrophages is thought to be beneﬁcial and required in circum-
stances where resolution of inﬂammation is needed, such as the
process of wound healing [37]. Interestingly, the present study
indicated that M-Ms differentiated in the presence of a glycol-
ysis inhibitor have sufﬁcient plasticity to become IL-10 producing,
M-M-like cells. It may  be possible that inhibition of glycolytic
pathway reﬂects the circumstance of malnutrition which is associ-
ated with inﬂammation of whole body or local tissue such as tumors
[40–42]. Collectively, our ﬁndings suggest that macrophages may
have plasticity to differentiate into a particular phenotype depend-
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ng not only on the cytokines but also on the metabolic state
ncluding the supply of glucose.
Several metabolites, including succinate and lactate, were
hown to be involved in regulating cytokine production by
acrophages [15,16]. Also, recent studies have described the anti-
nﬂammatory properties of pyruvate or ethyl pyruvate [43,44].
thyl pyruvate is a hyperpermeable analog of pyruvate [45].
hese molecules are reported to inhibit the production of pro-
nﬂammatory cytokines (IL-6, TNF, etc.) from macrophages by
cting as an effective scavenger of reactive oxygen species [44,46].
he present study showed that the addition of pyruvate alone to
ifferentiating M-Ms did not suppress IL-6 production, whereas
he addition of pyruvate to M-Ms differentiated in the presence
f DCA signiﬁcantly reduced the production of IL-6 enhanced by
CA. These observations provide a new insight that endogenous
yruvate plays pivotal roles in the differentiation of regulatory
acrophages to acquire its characteristic cytokine production
attern. In contrast, pyruvate had no effect on IL-10 produc-
ion, suggesting the involvement of other metabolites or that the
xternally added pyruvate was not sufﬁcient for the complete
ifferentiation of M-Ms. Although ethical and technical restric-
ion of using human monocytes makes it difﬁcult to study entire
echanism of our observations, more detailed investigation on the
etabolic pathways including activities of regulatory enzymes and
evels of key metabolites may  reveal the mechanisms how pyruvate
nd inhibitors affect the differentiation of macrophages.
Recently, Tan et al. reported that mitochondrial respiration
hich is enhanced by knockdown of PDK1 stimulated M2  activa-
ion of macrophages [47]. In this paper, they treated macrophages
y IL-4 for several hours to enhance M2  activation, and found
hat mitochondrial respiration is required for the early activa-
ion of M2  macrophages. PDK1 knockdown should have similar
ffects on the differentiation of macrophages to the addition of DCA
hich inhibits PDK [23]. However, our study indicated that DCA
uppressed the differentiation of macrophages toward regulatory
henotype. In our study, we incubated monocyte with M-CSF for
 days to differentiate into regulatory macrophages, and evaluated
he effect of DCA during the whole period of differentiation. The dif-
erence of the protocol and the period of observation between these
tudies would account for the discrepancy between these ﬁndings.
hat is, DCA might induce the M2  activation of already differenti-
ted macrophages, however, it might inhibit the differentiation of
onocyte to a regulatory phenotype.
Treatment of cancers is thought to be enhanced by drugs that
odulate metabolic pathways [25,48]. It may  be possible that mod-
lation of macrophage differentiation to a regulatory phenotype
y the inhibition of metabolic pathways also contribute to cancer
reatment, because tumor associated macrophages exhibit reg-
latory macrophage phenotype and play critical roles in tumor
rogression by constituting its microenvironment [49,50].
In summary, our results reveal a new aspect of regulatory
acrophage differentiation in which glycolytic pathway facili-
ates this process by supplying pyruvate. Our ﬁndings suggest that
acrophages will change their phenotype dramatically depending
n their circumstances including its metabolic state.
. Conclusion
In this study we showed that inhibition of glycolysis during
ifferentiation of regulatory macrophages resulted in a loss of
heir characteristics including cytokine production patterns and
lteration of gene expression patterns relates to macrophage differ-
ntiation. These effects were reversed by the addition of pyruvate
o the culture media at least in part. It was indicated that glycolytic
athway plays important roles in macrophage differentiation to
[etters 176 (2016) 18–27
be a regulatory phenotype, and pyruvate may  be one of the key
metabolites in this process.
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